Duloxetine delayed-release capsules exceed the interim nitrosamine impurity limit
Duloxetine Delayed-Release 20 mg capsules packaged by Direct Rx are being recalled because a nitrosamine drug substance related impurity was present above the proposed interim limit. 16 bottles affected.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: Risk-of-harm product: a nitrosamine impurity measured above the named interim limit, with no injury reported in the source.
Plain-English summary
Duloxetine D/R, 20 mg, 30 capsules per bottle, prescription only, packaged and distributed by Direct Rx and distributed by Breckenridge Pharmaceuticals, Inc. of Berlin, Connecticut, NDC 61919-422-30, is being recalled. The action covers 16 bottles.
The stated reason is CGMP deviations: the presence of a nitrosamine drug substance related impurity above the proposed interim limit. The FDA classified the action as Class II.
The affected lot is 02AU2406, expiring 01/31/2027. Distribution was nationwide.
Patients holding the affected lot should speak to their pharmacist or prescriber before stopping treatment, and pharmacies should follow the instructions issued by the distributor.
The recalled product
- Product
- Duloxetine D/R, 20 mg, 30 Caps, 30-count bottle, RX Only, Packaged & Distributed by: Direct Rx, Dist. By Breckenridge Pharm., Inc., Berlin, CT 06037, NDC 61919-422-30
- Manufacturer
- Direct Rx
- Category
- Drug — Delayed-release capsule
- Affected units
- 16
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: 02AU2406
- Exp 01/31/2027
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 2 recalled by Direct Rx under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 2 products in this recall →Related recalls
Same manufacturer · Direct Rx
See all →- ModerateDuloxetine 30 mg capsules recalled for impurity above FDA limits
FDA (Drugs) · 2026-07-01
- HighDirect Rx duloxetine 30 mg capsules exceed the interim nitrosamine limit
FDA (Drugs) · 2025-08-13
- ModerateCiprofloxacin Ophthalmic Solution Recalled for Defective Container Cap
FDA (Drugs) · 2025-04-23
- HighGeneric Ibuprofen 800mg Recalled Due to Failed Impurity and Degradation Specifications
FDA (Drugs) · 2024-11-13
- ModerateAlprazolam 1 mg tablets recalled due to manufacturing contamination concerns
FDA (Drugs) · 2023-04-12
Same hazard · nitrosamine
See all →- SevereFDA Recalls Mirabegron Tablets Over Nitrosamine Impurity
FDA (Drugs) · 2026-08-12
- HighDuloxetine 30mg delayed-release capsules exceed nitrosamine impurity interim limit
FDA (Drugs) · 2026-06-17
- HighDuloxetine 60mg delayed-release capsules exceed nitrosamine impurity interim limit
FDA (Drugs) · 2026-06-17
- ModerateBisoprolol and hydrochlorothiazide tablets recalled over a nitrosamine impurity
FDA (Drugs) · 2026-02-11
- HighClomipramine 25 mg capsules recalled over nitrosamine above the intake limit
FDA (Drugs) · 2025-11-12